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Abstract
Mutations in the humanMECP2 gene cause Rett syndrome (RTT), a severe neurodevelop-
mental disorder that predominantly affects girls. Despite decades of work, the molecular
function of MeCP2 is not fully understood. Here we report a systematic identification of
MeCP2-interacting proteins in the mouse brain. In addition to transcription regulators, we
found that MeCP2 physically interacts with several modulators of RNA splicing, including
LEDGF and DHX9. These interactions are disrupted by RTT causing mutations, suggesting
that they may play a role in RTT pathogenesis. Consistent with the idea, deep RNA
sequencing revealed misregulation of hundreds of splicing events in the cortex ofMecp2
knockout mice. To reveal the functional consequence of altered RNA splicing due to the
loss of MeCP2, we focused on the regulation of the splicing of the flip/flop exon ofGria2 and
other AMPAR genes. We found a significant splicing shift in the flip/flop exon toward the flop
inclusion, leading to a faster decay in the AMPAR gated current and altered synaptic trans-
mission. In summary, our study identified direct physical interaction between MeCP2 and
splicing factors, a novel MeCP2 target gene, and established functional connection
between a specific RNA splicing change and synaptic phenotypes in RTT mice. These
results not only help our understanding of the molecular function of MeCP2, but also reveal
potential drug targets for future therapies.
Author Summary
Rett syndrome (RTT) is a debilitating neurodevelopmental disorder with no cure or effec-
tive treatment. To fully understand the disease mechanism and develop therapies, it is nec-
essary to study all aspects of the molecular function of methyl-CpG binding protein 2
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(MeCP2), mutations in which have been identified as the genetic cause of RTT. Over the
years, MeCP2 has been shown to maintain DNAmethylation, regulate transcription and
chromatin structure, control microRNA processing, and modulate RNA splicing. Among
these known functions, the role of MeCP2 in modulating RNA splicing is less well under-
stood. We took several unbiased approaches to investigate the howMeCP2 may regulate
splicing, what splicing changes are caused by the loss of MeCP2, and what functional con-
sequences are caused by altered splicing. We discovered that MeCP2 interacts with splic-
ing factors to regulated the splicing of glutamate receptor genes, which mediate the vast
majority of excitatory synaptic transmission in the brain; and linked the altered splicing of
glutamate receptor genes to specific synaptic changes in a RTT mouse model. Our findings
not only advance the understanding of RTT disease mechanism, but also reveal a potential
drug target for future development of therapies.
Introduction
Rett syndrome (RTT) is a progressive neurodevelopmental disorder that predominantly affects
females[1, 2]. Classic RTT patients develop normally in the first 6–18 months, and then
undergo a rapid regression of higher brain functions that eventually leads to the loss of speech
and purposeful hand movement, microcephaly, dementia, ataxia and seizure[3]. Mutations in
the human X-linked methyl-CpG-binding protein 2 (MECP2) gene are responsible for over
90% of classic RTT cases[4]. MeCP2 is abundantly expressed in the mammalian central ner-
vous system (CNS) and binds to methylated CpG site throughout the genome[5]. Despite
decades of work, the underlying molecular mechanism of how mutations ofMECP2 lead to
RTT is not fully understood.
In order to reveal the RTT disease mechanism, it is necessary to study the molecular function
of MeCP2. Previous research on the molecular function of MeCP2 has focused on the localiza-
tion of MeCP2 in the nucleus and the proteins that physically interact with MeCP2. At the
microscopic level, MeCP2 appears to be colocalized with heterochromatin and thus is hypothe-
sized to induce large-scale chromatin reorganization during terminal differentiation[6]. At the
genomic level, MeCP2 can bind to unmethylated DNA[7], methylated cytosine[5], and hydroxy-
methylated cytosine[8], and may preferentially modulate the expression of long genes[9]. In par-
allel to research on MeCP2 localization, many proteins have been identified to physically
interact with MeCP2. Based on the known functions of identified MeCP2-interacting proteins,
previous studies have suggested a role for MeCP2 in maintaining DNAmethylation[10], regulat-
ing transcription[11–16], chromatin structure[17–22], and RNA processing[23–25]. Future
effort to combine the insights from the two approaches described above may allow more detailed
understanding of the regulation of each of these specific protein-protein interactions across the
entire genome, as well as the relevance of each interaction to RTT disease pathogenesis.
Misregulation of RNA alternative splicing has been implicated in a number of neurological
disorders, which can be classified into two categories: cis-acting splicing disorder and trans-act-
ing disorder[26]. Cis-acting disorder is caused by mutations that affect splicing of the mutant
gene itself and therefore the function of that gene. An example of this type is frontotemporal
dementia with Parkinsonism linked to chromosome 17 (FTDP-17), in which mutations in the
MAPT (Tau) gene alter the function of Tau by increasing the exon 10 containing isoform[27].
In contrast, trans-acting disorders are caused by the loss of function of genes with regulatory
roles in RNA splicing. For instance, the loss of survival motor neuron protein 1 (SMN1) func-
tion affects biogenesis of small nuclear RNA (snRNA) and lead to widespread splicing changes
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in spinal muscular atrophy (SMA)[28]. Relevant to RTT, the Zoghbi lab has identified RNA-
dependent interaction between MeCP2 and Y box-binding protein 1 (YB1) in cultured cells,
and further reported many altered RNA splicing events in a mouse model of RTT[23]. How-
ever, it is not clear if the splicing alterations are indeed dependent on the MeCP2/YB1 interac-
tion and no link has been discovered between any gene-specific splicing change and specific
neuronal phenotypes in RTT. Therefore the mechanistic and functional links between MeCP2,
splicing regulation, and RTT phenotypes remain elusive.
To facilitate systematic identification of MeCP2-interacting proteins in the brain, we created
a knockin mouse line (Mecp2-Flag) that expresses Flag-tagged MeCP2 from the endogenous
Mecp2 locus[29]. This unique tool gives us two main advantages. First, it ensures that the
MeCP2-Flag protein is expressed at the physiological level, so that non-specific protein-protein
interactions caused by the overexpression of MeCP2-Flag is minimized. Second, it allows us to
use a highly efficient anti-Flag antibody in the co-immunoprecipitation. The choice of antibody
is not a trivial issue, because in the past, different anti-MeCP2 antibodies in co-immunoprecip-
itation experiments have generated conflicting results in the identification of MeCP2-interact-
ing proteins[30, 31]. Mass spectrometry analysis of proteins co-immunoprecipitated by the
anti-Flag antibody from the nuclear extract prepared from theMecp2-Flagmouse brains
showed that MeCP2 interacted with multiple splicing factors. Some of these physical interac-
tions were disrupted by RTT-causing mutations in MeCP2. Furthermore, ChIP-seq analysis of
revealed MeCP2 occupancy at exon/intron injections, which provides additional support of the
role for MeCP2 in modulating alternative splicing. Consistent with previous findings, hundreds
of splicing events were found to be misregulated in the cortex ofMecp2 knockout (KO) mice.
More importantly, a specific splicing change in theMecp2 KO cortex-a shift in the balance
between the flip and flop exon in the AMPA receptor (AMPAR) genes was causally linked to
synaptic phenotypes of faster desensitization kinetics of AMPAR-gated current and altered
synaptic transmission. Together, our findings substantiate the role of MeCP2 in regulating
alternative splicing of RNA by revealing direct physical interaction between MeCP2 and multi-
ple splicing factors, association of MeCP2 at exon/intron junction, and providing the first func-
tional link between a specific splicing alteration and synaptic phenotypes in RTT mice.
Results
Systematic identification of MeCP2-interacting proteins in the brain
To facilitate identification of MeCP2-interacting proteins in the mouse brain, we generated the
Mecp2-Flag knockin mouse line that expresses Flag-tagged wild-type MeCP2 from the endoge-
nous locus. We purified nuclei from the brains of maleMecp2-Flagmice, prepared nuclear
extract and performed co-immunoprecipitation (co-IP) using the anti-Flag antibody. Eluted
protein sample was then subjected to protein identification by mass spectrometry. Forty-eight
proteins were identified using highly stringent statistical filters (S1 Table). Identified proteins
included previously known MeCP2-interacting transcriptional regulators and chromatin
remodeling proteins, such as HDAC1 and components of the SWI/SNF complex. Consistently,
gene ontology (GO) analysis showed that proteins identified by co-IP/MS were enriched with
GO terms of chromatin organization, chromatin modification and regulation of transcription.
Interestingly, these proteins were also enriched for RNA splicing (Fig 1a). MeCP2 has been
implicated in regulating splicing, but its role in pre-mRNA splicing has not been studied exten-
sively. Therefore we decided to focus our study on the interaction between MeCP2 and several
splicing factors.
To validate the physical interaction between MeCP2 and splicing factors, we performed
anti-Flag co-IP in nuclear extract from theMecp2-Flag knockin mouse brain and probed it
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with antibodies against TDP-43, LEDGF, DHX9, FUS, hnRNP H, and hnRNP F, respectively.
Western blot results showed that TDP-43, LEDGF, DHX9 and FUS were co-immunoprecipi-
tated with MeCP2, whereas hnRNP H and hnRNP F were not (Fig 1b). Next, we performed
reverse co-IP and detected MeCP2 in immunoprecipitate of anti-TDP-43, anti-LEDGF, anti-
DHX9, anti-FUS, and anti-hnRNPH+F (Fig 1c), further confirming that MeCP2 physically
interacts with these proteins in the mouse brain. In addition, the interaction between MeCP2
and splicing factors were not sensitive to Benzonase treatment, which digest and remove all
nucleic acids, suggesting that these interactions were most likely direct interactions indepen-
dent of either DNA or RNA (S1 Fig).
RTT mutations disrupt interactions between MeCP2 and LEDGF or
DHX9
The interaction between MeCP2 and LEDGF has been previously reported in cancer cells[32],
but not in the brain. MeCP2 interacts with the N-terminal PWWP-CR1 domain of LEDGF,
but which domain of MeCP2 that LEDGF binds to is not defined. DHX9 has recently been
revealed as an interacting partner of MeCP2[33], but the interaction domain is not known
either. To examine which domain of MeCP2 is required for interaction with LEDGF and
DHX9, we expressed HA-tagged MeCP2 with different deletions (Fig 2a) and Myc-tagged full-
length LEDGF/p52, LEDGF/p75 and DHX9, respectively, in HEK293 cells. Co-IP with anti-
HA antibody followed by Western blot with anti-Myc antibody showed that deletion of amino
acids 163–380 of the MeCP2 protein significantly reduced the interaction between MeCP2 and
LEDGF/p52, LEDGF/p75 or DHX9 (Fig 2b and 2c; S2a Fig). Reverse co-IP with anti-Myc anti-
body followed by Western blot with anti-HA antibody also demonstrated that amino acids
163–380 of the MeCP2 protein was required for interaction between MeCP2 and LEDGF/p52
Fig 1. MeCP2 interacts with multiple splicing regulators. (a) Gene ontology (GO) analysis of proteins identified from anti-Flag co-
immunoprecipitation and mass spectrometry (Co-IP/MS) analysis inMecp2-Flag knockin mouse brain. Top five GOTERM_BP_FAT terms
were shown and –log10 Benjamini P-value is plotted. (b) Western blot validation of interactions between MeCP2 and splicing regulators
identified in Co-IP/MS. Anti-Flag immunoprecipitate in nuclear extract fromWT andMecp2-Flag knockin mouse brain is resolved in
SDS-PAGE and probed with antibodies against indicated proteins. (c) Western blot analysis of MeCP2 in anti-TDP-43, anti-LEDGF, anti-
DHX9, anti-FUS and anti-hnRNP F+H immunoprecipitate. Rabbit (Rb) IgG is negative control for rabbit antibody (anti-TDP-43, LEDGF,
DHX9 and FUS) and mouse (Ms) IgG is negative control for mouse antibody (anti-hnRNP F+H).
doi:10.1371/journal.pgen.1006129.g001
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(S2b Fig). Collectively, these results strongly suggested that the transcription repression
domain (TRD) of MeCP2 is essential for the interaction of MeCP2 with RNA binding proteins.
Several RTT disease causing mutations locate in the region of amino acids 163–380 (R168X,
R255X, R270X and R294X) and may disrupt the TRD domain, therefore we asked whether
these mutations affect the interaction between MeCP2 and LEDGF or DHX9. To test this, we
co-transfected MeCP2 constructs encoding MeCP2WT, MeCP2R168X, MeCP2R255X,
MeCP2R270X, and MeCP2R294X, respectively, with LEDGF/p52 or DHX9 in HEK293 cells. Co-
IP assay showed that interaction between LEDGF/p52 and MeCP2R168X, MeCP2R255X, and
MeCP2R270X was significantly impaired (Fig 2d and 2e). Interestingly, the interaction between
MeCP2R294X (retaining a large fraction of TRD) and LEDGF/p52 was not significantly different
from that between wild type MeCP2 and LEDGF/p52, suggesting that amino acids 270–294 of
MeCP2 are required for its binding to LEDGF/p52 (Fig 2d and 2e). Similarly, we found that
MeCP2R168X and MeCP2R255X interacted poorly with DHX9, while MeCP2R270X and
Fig 2. RTTmutations disrupt MeCP2 interaction with LEDGF and DHX9. (a) Schematic diagram of HA-MeCP2 constructs used in this study. The
methyl-CpG-binding domain (MBD) domain is shown in yellow and the transcription repression domain (TRD) in blue. (b) Western blot analysis of
Myc-LEDGF/p52 in anti-HA immunoprecipitate (top panel) from cells transfected with different combinations of plasmids as labeled on top.
HA-MeCP2 (middle panel) and Myc-LEDGF/p52 (bottom panel) in input were also analyzed by western blot. (c) Western blot analysis of Myc-DHX9 in
anti-HA immunoprecipitate (top panel) from cells transfected with different combinations of plasmids as labeled on top. HA-MeCP2 (middle panel) and
Myc-DHX9 (bottom panel) in input were also analyzed byWestern blot. (d) Representative western blot analysis of Myc-LEDGF/p52 in HA
immunoprecipitate (top panel) from cells transfected with different combinations of plasmids as labeled on top. HA-MeCP2 (middle panel) and Myc-
LEDGF/p52 (bottom panel) in input were also analyzed byWestern blot. (e) Quantification of Myc-LEDGF/p52 IP over input signal intensity of three
independent experiments. Error bar represents S.E.M, **P < 0.01, *P < 0.05; two-tailed t-test. (f) RepresentativeWestern blot analysis of Myc-DHX9
in HA immunoprecipitate (top panel) from cells transfected with different combinations of plasmids as labeled on top. HA-MeCP2 (middle panel) and
Myc-DHX9 (bottom panel) in input were also analyzed byWestern blot. (g) Quantification of Myc-DHX9 IP over input signal intensity of four
independent experiments. Error bar represents S.E.M, **P < 0.01, *P < 0.05; two-tailed t-test.
doi:10.1371/journal.pgen.1006129.g002
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MeCP2R294X had intact binding capability, indicating that amino acids 255–270 of MeCP2 are
required for its binding to DHX9 (Fig 2f and 2g).
Misregulation of alternative splicing in the cortex ofMecp2 KOmouse
The newly identified interactions between MeCP2 and multiple splicing factors prompted us to
determine whether there are widespread RNA splicing changes upon loss of MeCP2. We con-
ducted high-throughput sequencing of RNA (RNA-Seq) from the cortex of wild type andMecp2
knockout (KO) mice. As a measure of the quality of the RNA-Seq data, we first examined
whether our data reflect transcriptional changes consistent with previous findings. We examined
transcriptional changes in our RNA-Seq data by applying a negative binomial model in edgeR
[34]. Recently, a meta-analysis of transcriptional changes across multiple brain regions inMecp2
KO or overexpression (OE) mouse identified 466 MeCP2-repressed genes based on high degree
of consistency (log2FC> 0 in KO or log2FC< 0 in OE in at least 7 out of 8 datasets; FC: fold
change)[9]. Of these genes, 315 genes (~68%) were also found to be up-regulated (log2FC[KO/
WT]> 0) in our analysis result, suggesting significant overlap between transcriptional changes
identified in our study and previous studies (S2 Table). In addition, we selected seven previously
knownmisregulated genes inMecp2 KO[9, 35] as well as six novel differentially expressed gene
identified by our study for further validation. qRT-PCR results show that all of them show simi-
lar changes as observed in our RNA-Seq data (Pearson’s r = 0.95) (S3 Fig). Taken together, these
data indicate that our RNA-Seq data are robust in identifying transcriptional changes.
Next, we applied the Mixture of Isoforms (MISO)[36] algorithm to the RNA-Seq data and
identified 263 alternative splicing (AS) events that were significantly changed in the cortex of
Mecp2 KOmice using a stringent filter (S3 Table; see Methods for detail). Loss of MeCP2
affects various types of AS events, including skipped exon (SE), mutually exclusive exons
(MXE), retained intron (RI), alternative 5’ ss exon (A5E), and alternative 3’ ss exon (A3E) (Fig
3a). Subsequent analysis indicated that although more RI or MXE events had slightly reduced
percent spliced in (PSI) value, SE, A5E and A3E events, which in total represented the majority
of events, had similar number of events with increased or decreased PSI (Fig 3b). These data
suggest the loss of MeCP2 affects alternative splicing in both directions, which is similar to the
knockdown or overexpression of a typical splicing factor[37, 38]. Additionally, functional
enrichment analysis using DAVID showed that genes with splicing changes were enriched
with splice variant, alternative splicing, phosphoprotein, cell junction, compositionally biased
region (Ser-rich) and plasma membrane part (S4a Fig). Interestingly, gene expression analysis
on the 232 genes associated with splicing changes revealed that the majority of them have simi-
lar total expression level between WT andMecp2 KO (only 15 genes show larger than 1.25-fold
change and only one shows larger than 1.5-fold change) (Fig 3c), suggesting that MeCP2-me-
diated transcriptional regulation and splicing regulation are independent of each other. To vali-
date the splicing changes, we performed qRT-PCR with isoform specific primers to evaluate 20
SE events. We observed consistent changes in 13 genes as identified by MISO (65%), including
6 events with decreased PSI and 7 events with increased PSI inMecp2 KO (S5 Fig). The overall
validation rate from our study of using biological replicates of tissue is comparable to the suc-
cess rate using cell lines in two recent studies (74% and 71%, respectively)[39, 40], when more
than 20 events were selected for validation.
To generalize our observation that loss of MeCP2 leads to global splicing changes, we ana-
lyzed RNA-Seq data generated fromMecp2 KO hypothalamus and visual cortex in two recent
studies[9, 35], respectively. Using a cutoff of |ΔPSI| 5% and Bayes factor1, 482 and 719 SE
events were identified by MISO to be changed inMecp2 KO hypothalamus and visual cortex,
respectively. 150 of the 482 SE events identified in theMecp2 KO hypothalamus and 171 of the
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719 SE events identified in theMecp2 KO visual cortex were also found in our study (S4–S6
Tables). We focused our meta-analysis on SE events because this is the best-annotated category
of alternative splicing events in the mouse genome. In summary, the large number of alterna-
tive splicing changes in independent RNA-seq data sets and the significant overlap between
data sets generated from different brain regions of different lines ofMecp2 KOmice at different
ages are consistent with the notion that loss of MeCP2 results in global splicing alterations.
To further study whether MeCP2 may be directly involved in modulating splicing, we exam-
ined MeCP2 occupancy across the genome. ChIP-Seq analysis was performed using the anti-
Flag antibody on chromatin prepared from the cortex of theMecp2-Flag knockin mice. 20,652
high confidence MeCP2 ChIP-seq peaks were identified (S7 Table, see Methods for detailed
description on ChIP-seq analysis and quality control statistics.). Based on statistical ranking
and robustness of primer design, 5 of the identified peaks were selected for independent valida-
tion (highlighted in S7 Table). ChIP-qPCR on a separate cohort ofMecp2-Flag mice detected
significant occupancy of MeCP2 at the genomic locations corresponding to these 5 peaks rela-
tive to Gapdh promoter (S7 Table). To gain an overall picture of MeCP2 distribution across the
Fig 3. Global splicing changes inMecp2 KOmouse cortex and enrichment of MeCP2 around the exon/intron boundary. (a)
Number of misregulated alternative splicing (AS) events by category inMecp2 KO cortex. (b) Relative fraction of each AS events type
positively or negatively affected by loss of MeCP2. (c) Histogram of total gene expression changes inMecp2 KO cortex for those 232
genes associated with splicing changes inMecp2 KO cortex. FC: fold change. (d) Functional enrichment analysis of genes with
MeCP2 peak(s) identified in ChIP-Seq data fromWTmouse cortex. Top six terms are shown and –log10 Benjamini P-value is plotted
for each GO term. (e) Read counts per millions of mapped reads (ChIP minus input) across regions spanning from 500bp upstream
and 500bp downstream of all exons. Coverage for ChIP and input data are calculated for each biological replicate and normalized to
be equal length across all the mm9 exons by sampling at equal intervals. Displayed is the average ChIP minus input profile of two
biological replicates. The graph is generated using ngs.plot[41].
doi:10.1371/journal.pgen.1006129.g003
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genome relative to genes, we examined the MeCP2 ChIP-seq signal in the 2kb region immedi-
ately upstream of all transcriptional start sites (TSS), the region from TSS to the transcription
end sites (TES), and the 2kb region immediately downstream of TES across the genome. This
analysis revealed that MeCP2 occupancy was depleted at promoters (~0 read count per million
mapped reads [ChIP minus Input] from TSS to -2,000bp. In contrast, MeCP2 binding is
enriched in the gene body (0.05–0.33 read count per million mapped reads [ChIP minus
Input] from TSS to TES, S4b Fig). To assess the correlation between MeCP2 ChIP-seq signal
and DNA methylation, we calculated the average percentage of mCG and mCH across all of
our MeCP2 ChIP-seq peaks using previously published whole genome base-resolution methyl-
ation data in mouse cortex [42], and found that the percentage of mCG in MeCP2 ChIP-seq
peaks is slightly higher than genome average (~83% vs 78%), and the percentage of mCH in
MeCP2 ChIP-seq peaks is significantly higher than genome average (2.78% vs 1.30%), suggest-
ing MeCP2 ChIP signal is correlated with mCH and mCG across the genome. These results are
consistent with several previous studies that demonstrated that MeCP2 occupancy tracks DNA
methylation across the genome[35, 43, 44]. Moreover, the average GC content in MeCP2
ChIP-seq peaks is ~53.8%, significantly higher the genome average of 42% [45]. The correla-
tion between MeCP2 occupancy and GC content is consistent with findings reported in earlier
this year [44]. Interestingly, gene ontology analysis found that genes with MeCP2 ChIP-seq
peak(s) were enriched with GO terms of alternative splicing (Fig 3d). Indeed, alignment of
MeCP2 ChIP-seq reads with the 5’ and 3’ ends of exons revealed a significant enrichment of
MeCP2 ChIP-seq peaks around the exon/intron boundary and over exons (Fig 3e). Consis-
tently, significant enrichment of hmC and mCG signals were also found at intron/exon bound-
ary and on exons, while a modest enrichment of mCH signal was observed at the 3’ end of
exons (S4c–S4e Fig). Taken together, the physical interaction between MeCP2 and splicing fac-
tors, the widespread changes in RNA splicing, and the enriched MeCP2 occupancy around
exon/intron boundary are consistent with each other and strongly suggest that MeCP2 could
play an important role in regulating alternative splicing.
Altered splicing of the AMPAR genes in the cortex ofMecp2 KOmice
Gria2 is a major component of the AMPA receptor (AMPAR), which mediates the vast major-
ity of fast synaptic transmission in the CNS. Two electrophysiologically distinct isoforms for
Gria2 are generated by a mutually exclusive splicing event of the Gria2 pre-mRNA. Depending
of the usage of either the flip or the flop exon, Gria2 pre-mRNA can be spliced into either the
flip or the flop isoform. Our RNA-Seq data revealed that ~ 51% of all Gria2 transcripts con-
tained the flip exon in wild type mice. In contrast, only ~ 28% Gria2 transcripts included the
flip exon in theMecp2 KOmice (Fig 4a). qRT-PCR analysis in a separate cohort of animals
confirmed a shift of flip/flop ratio toward a flop dominant state inMecp2 KOmice, while the
total expression level of the Gria2 gene remained unchanged (Fig 4b and 4c). The reduction of
flip/flop ratio inMecp2 KOmice are not likely due to delayed development of the brain because
the flip isoform is more abundant during early brain development and the flop isoform gradu-
ally increases to a comparable level of the flip isoform toward adulthood[46].
Since alternative splicing of flip/flop exons is a common feature in all AMPAR genes, we
asked whether similar changes also occurred in the Gria1, Gria3, and Gria4 genes. Quantifica-
tion result showed that flip/flop ratio of Gria1, Gria3, and Gria4 genes was significantly
reduced in the cortex ofMecp2 KO mice (Fig 4d), implicating a biased usage of flop exon in the
mature transcripts of all AMPAR genes. Importantly, the total mRNA level of Gria1 was
unchanged and only subtle trend of decreasing Gria3 and Gria4mRNA level was observed in
Mecp2 KOmice (Fig 4e).
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Fig 4. Loss of MeCP2 affects flip/flop splicing of AMPAR genes. (a) Reads distribution surrounding the
flip and flop exons ofGria2 locus from RNA-Seq data of two pairs of WT andMecp2 KOmouse cortex.
Percentage of flip isoform (% flip) for each sample is estimated by Mixture of Isoform pipeline (MISO) and
plotted on the right. (b) Quantification of flip/flop ratio ofGria2 gene in the cortex of WT andMecp2 KOmice.
Mean ± S.E.M is plotted. n = 8 per genotype. *** P < 0.001; two-tailed t-test. (c) Quantification ofGria2 total
mRNA level in the cortex of WT andMecp2 KOmice. Mean ± S.E.M is plotted. n = 8 per genotype. (d)
Quantification of the flip/flop ratio ofGria1,Gria3 andGria4 in the cortex of WT andMecp2 KOmice.
Mean ± S.E.M is plotted. n = 8 per genotype. *** P < 0.001; two-tailed t-test. (e) Quantification ofGria1, Gria3
and Gria4 total mRNA level in the cortex of WT andMecp2 KOmice. Mean ± S.E.M is plotted. n = 8 per
genotype. (f) Quantification of the flip/flop ratio ofGria1,Gria2, Gria3 andGria4 in the cortex of WT and
Mecp2-/+ female mice. Mean ± S.E.M is plotted. n = 4 per genotype. * P < 0.05, ** P < 0.01; two-tailed t-test.
(g) Quantification ofGria1,Gria3 and Gria4 total mRNA level in the cortex of WT andMecp2-/+ female mice.
Mean ± S.E.M is plotted. n = 4 per genotype.
doi:10.1371/journal.pgen.1006129.g004
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Interestingly, analysis of RNA-Seq data from visual cortex and hypothalamus ofMecp2 KO
mice also showed that percentage of flip isoform is significantly decreased (S8 Fig). Note that
these two studies used the Bird allele (Mecp2tm1.1Bird) and our data was generated from the Jae-
nisch allele (Mecp2tm1.1jae). The consistent flip/flop splicing changes across different brain
regions from different knockout mouse lines suggested that reduction of flip/flop ratio is a
common defect due solely to loss of MeCP2. More importantly, we also found that the percent-
age of flip isoform in the hypothalamus ofMecp2 OE mice was significantly increased, which is
opposite to the changes inMecp2 KO (S8 Fig). Together, these results strongly suggest that
MeCP2 directly modulates the regulation of Gria2 flip/flop splicing.
Finally, we tested whether splicing alteration of AMPAR genes also occurs in the cortex of
heterozygous femaleMecp2-/+ mice. Although not as drastic as that observed inMecp2 KO
male mice,Mecp2-/+ mice also displayed a significant reduction of flip/flop ratio in Gria1,
Gria2, Gria3, and Gria4 (Fig 4f). Similar toMecp2 KOmale mice,Mecp2-/+ mice had
unchanged total mRNA level in all four AMPAR genes (Fig 4g). These data suggest similar
change in flip/flop usage may exist in female RTT patients.
LEDGF is involved in the regulation of Gria2 flip/flop splicing
To determine how loss of MeCP2 affects the splicing of flip/flop exon, we focused on the Gria2
gene to explore the potential involvement of several recent models of splicing regulation. Mod-
ulation of PolII elongation rate has been proposed as one model of how epigenetic mechanisms
influence splicing. Slow PolII elongation rate allows longer time for spliceosome to assemble
and hence increase the chance of the alternative exon being included in the mature transcript
[47]. A recent study suggested that MeCP2 is enriched in particular alternative exons and facili-
tates exon inclusion by pausing PolII in cultured cells[48]. We set out to test whether MeCP2
regulates Gria2 flip/flop splicing through similar mechanism in the brain. Chromatin immuno-
precipitation (ChIP) followed by qRT-PCR showed a significant enrichment of MeCP2 on the
flip and flop exons of Gria2 gene (Fig 5a). However, no significant difference in PolII occu-
pancy on the flip and flop exons between the wild type andMecp2 KOmice was found by PolII
ChIP (Fig 5b), suggesting the involvement of a PolII-independent mechanism underlying the
flip/flop splicing change inMecp2 KO brain. Another interesting epigenetic model for alterna-
tive splicing regulation is that histone modification can be bound by adaptor proteins which in
turn recruit specific splicing factor to alternative exons[47]. It has been previously shown that
trimethylated histone H3 lysine 36 (H3K36me3) is enriched on exons and can be bound by
LEDGF, which recruits splicing factors such as SRSF1 to regulate splicing[49]. Although signif-
icant LEDGF occupancy was detected on the flip and flop exons (Fig 5c), no significant differ-
ence in the occupancy of H3K36me3 on the flop and flip exons was detected between the wild
type andMecp2 KO brain (Fig 5d).
To determine whether LEDGF is functionally involved in the regulation of Gria2 flip/flop
splicing, we tested the effect of knockdowning LEDGF on flip/flop ratio in a neuroblastoma
cell line, Neuro-2A, using a Gria2minigene. The Gria2minigene spans the genomic region
from exon 13 to exon 15 of Gria2 (S9a Fig, either the flip or flop exon can be included as exon
14). As a control, we co-transfectedMecp2 shRNA, Gria2 minigene along with a MeCP2 over-
expression plasmid into Neuro-2a cells and found that flip/flop ratio is significantly reduced
uponMecp2 knockdown (Fig 5e and 5f), indicating that this artificial assay is capable of discov-
ering factors that potentially affect flip/flop splicing. Next, we transfected a Ledgf shRNA in the
cells and tested its effect on flip/flop splicing. Similar toMecp2 knockdown, Ledgf knockdown
also leads to a reduction of flip/flop ratio (Fig 5g and 5h), suggesting that LEDGF is function-
ally involved in the regulation of Gria2 flip/flop splicing.
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Fig 5. LEDGF is involved in regulation of Gria2 flip/flop splicing. (a) ChIP-qPCR analysis of MeCP2
occupancy onGapdh promoter,Gria2 flip and flop exon inMecp2-Flagmouse cortex. pr: promoter. Mean ± S.E.
M is plotted. n = 4 per genotype. * P < 0.05; one-way ANOVA followed with Holm-Sidak’s multiple comparisons
test. (b) ChIP-qPCR analysis of PolII occupancy onGria2 flip and flop exon in WT andMecp2 KO cortex.
Mean ± S.E.M is plotted. n = 4 per genotype. (c) ChIP-qPCR analysis of LEDGF occupancy onGria2 flip and flop
exon in WTmouse cortex. Mean ± S.E.M; n = 5; *** P < 0.001; one-way ANOVA followed with Holm-Sidak's
multiple comparisons test. (d) ChIP-qPCR analysis of H3K36me3 occupancy onGria2 flip and flop exons in WT
andMecp2 KO cortex. n = 4 per genotype. (e-g) Representative Western blot analysis of MeCP2 (e),
quantification of MeCP2 protein level (f), and flip/flop ratio (g) in Neuro-2A cells co-transfected withMecp2
shRNA plasmid, MeCP2 expression plasmid and Gria2 minigene plasmid. Mean ± S.E.M of three independent
experiments, * P < 0.05, *** P < 0.001; two-tailed t-test. (h-j) Representative Western blot analysis of LEDGF
(h), quantification of LEDGF protein level (i), and flip/flop ratio (j) in Neuro-2A cells co-transfected with Ledgf
shRNA plasmid and Gria2 minigene plasmid. Mean ± S.E.M of three (i) or four (j) independent experiments, **
P < 0.01; two-tailed t-test.
doi:10.1371/journal.pgen.1006129.g005
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Functional link between altered flip/flop splicing and synaptic
phenotypes in theMecp2 KOmice
Flip/flop exon encodes a 38 amino acids sequence in the ligand binding domain of AMPARs
that controls desensitization rate. Compared to flip-containing receptors, flop-containing
receptors desensitize with faster kinetics[50, 51]. To determine the functional consequence of
altered flip/flop splicing in the cortex ofMecp2 KOmice, we performed outside-out patch
clamp recording of glutamate-evoked current on layer 2/3 pyramidal neurons in acute brain
slices. We found that the decay time constant τ was significantly reduced inMecp2 KOmice
(Fig 6a and 6b). In addition to evoked response, regular whole cell patch clamp recording of
spontaneous synaptic events also detected a faster decay in miniature excitatory postsynaptic
current (mEPSC) in layer 2/3 pyramidal neurons from theMecp2 KOmice. Finally, bath appli-
cation of cyclothiazide (CTZ), a positive allosteric modulator of AMPARs that inhibits desensi-
tization of AMPARs[52], slowed down the decay kinetics inMecp2 KO slice to a comparable
level of wild type cells (Fig 6c and 6d). Together, these results uncover a previously unappreci-
ated defect of faster desensitization kinetics of AMPAR-gated current in theMecp2 KOmice,
which correlates with altered flip/flop splicing and can be modulated by pharmacological
reagents.
To causally link the change in flip/flop splicing and the altered AMPAR desensitization
kinetics, we used engineered splicing factors (ESF)[53, 54] to specifically manipulate flip/flop
splicing in the brain ofMecp2 KOmice. ESF is composed of a sequence-specific RNA-binding
domain derived from human Pumilio1 (PUF domain) and a functional domain that suppresses
(Gly domain) or enhances (SR domain) inclusion of a specific exon. We evaluated the effect of
four ESFs (ESF-flop-Gly [flop suppressor], ESF-flop-SR [flop enhancer], ESF-flip-Gly [flip sup-
pressor] and ESF-flip-SR [flip enhancer]) on flip/flop splicing using a Gria2minigene (S9a
Fig). We found that ESF-flop-Gly significantly increased the flip/flop ratio (Fig 6e), an effect
opposite to the change we observed in the cortex ofMecp2 KOmice. Moreover, ESF-flop-Gly
didn’t change the level of total Gria2minigene (Fig 6f).
To further test the effect of ESF-flop-Gly on flip/flop splicing of the endogenous Gria2 tran-
script in neurons, we infected primary cortical neurons with adeno-associated virus (AAV)
encoding either mCherry alone or ESF-flop-Gly and mCherry. As expected, AAV-ESF-flop-
Gly-mCherry significantly altered the flip/flop splicing balance to favor the use of the flip exon
(S9b and S9c Fig), suggesting that ESF-flop-Gly could be used in vivo to reverse the flip/flop
splicing defect inMecp2 KOmice. To that end, we injected lentivirus expressing ESF-flop-Gly
into the cortex ofMecp2 KOmice, and measured the decay time constant τ of glutamate-
evoked AMPAR-gated current in the outside-out patch clamp mode in acute brain slices 2
weeks post injection. Compared to neurons infected with control virus (KO+Ctrl), ESF-flop-
Gly expressing neurons (KO+ESF) had a significant larger decay time constant τ, which was
indistinguishable from that of WT cells (Fig 6g). These results strongly suggest that altered flip/
flop splicing is required for a specific synaptic phenotype in theMecp2 KOmice.
To further examine the effect of altered flip/flop splicing on synaptic transmission, we
applied repetitive stimulation on the neurons in an interval of 100 ms and recorded the
AMPAR-gated current. Upon repetitive stimulation, a fraction of AMPA receptors desensitizes
and the short interval between stimulation does not allow full recovery. As a result, fewer
AMPA receptors can respond to the subsequent stimulation and therefore current diminished.
Comparing to WT neurons, KO neurons displayed even more drastic decrease in current
amplitude over the course of five stimulations (Fig 6h and 6i). This difference could be partially
due to a higher percentage of flop isoform that are more easily desensitized in the KO neurons.
Consistent with this hypothesis, overexpressing ESF-flop-Gly in KO neurons partially rescued
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Fig 6. Altered AMPA receptor decay kinetics and synaptic transmission inMecp2KO cortical neurons can be reversed by ESF. (a)
Representative sample trace of glutamate-evoked current in WT andMecp2 KO cortical neurons. Scale bar = 15ms. (b) Quantification of decay time
constant τ of glutamate-evoked current in WT andMecp2 KO cortical neurons. Mean ± S.E.M is plotted. n = 37 for WT, n = 33 for KO. ** P < 0.01;
two tailed t-test. (c) Representative mEPSC sample trace in WT andMecp2 KO cortical neurons with or without CTZ treatment. Scale bar = 10ms.
(d) Quantification of decay time constant τ of mEPSC. Mean ± S.E.M is plotted. n = 42 for WT, n = 46 for KO, n = 38 for KO + CTZ. ** P < 0.01; one-
way ANOVA with Tukey’s multiple comparisons test. (e-f) qRT-PCR analysis the flip/flop ratio (e) and totalGria2minigene (f) expression in HEK 293
cells co-transfected with indicated ESF and theGria2minigene. Mean ± S.E.M is plotted. n = 4 for each group. * P < 0.05, *** P < 0.001; two tailed t-
test. (g) Quantification of decay time constant τ of glutamate-evoked current in WT,Mecp2 KO (KO+Ctrl) andMecp2 KO cortical neurons infected
with ESF-flop-Gly lentivirus (KO+ESF). Recording was done on acute slice frommouse infected with lentivirus two weeks after stereotaxic injection.
Mean ± S.E.M is plotted. n = 50 for WT, n = 26 for KO+Ctrl, n = 27 for KO+ESF. ** P < 0.01, *** P < 0.001; one-way ANOVA with Tukey’s multiple
comparisons test. (h) Representative sample trace of AMPAR-mediated current in response to repetitive stimulations in WT andMecp2 KO neurons
infected with control or ESF-flop-Gly lentivirus (KO+Ctrl or KO+ESF). Scale bar, 100ms. (i) Relative current amplitude of the xth stimulation to first
stimulation in WT andMecp2 KO neurons infected with either control or ESF-flop-Gly lentivirus (KO+Ctrl or KO+ESF). Mean ± S.E.M is plotted.
n = 36 for WT, n = 18 for KO+Ctrl, n = 18 for KO+ESF. Asterisk denotes P-value for comparison betweenWT and KO+Ctrl, *** P < 0.001. Pound
sign denotes P-value for comparison between KO+ESF and KO+Ctrl, # P < 0.05, ## P < 0.01; repeated measures two-way ANOVA with Tukey’s
multiple comparisons test. (j) Quantification of decay time constant τ of glutamate-evoked current in neurons infected with shCtrl or shLedgf
lentivirus. Mean ± S.E.M is plotted. n = 13 for shCtrl, n = 12 for shLedgf, * P < 0.05; two-tailed t-test. (k) Representative sample trace of AMPAR-
mediated current in response to repetitive stimulations in neurons infected with shCtrl or shLedgf lentivirus. Scale bar, 100ms. (l) Relative current
amplitude of xth stimulation to first stimulation in neurons infected with shCtrl or shLedgf. Mean ± S.E.M is plotted. n = 12 for each group, ***
P < 0.001; repeated measures two-way ANOVA with Tukey's multiple comparisons test.
doi:10.1371/journal.pgen.1006129.g006
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this phenotype (Fig 6h and 6i). These data suggest the altered flip/flop splicing ratio has impor-
tant impact on synaptic transmission in theMecp2 KO cortex, which can be reversed by ESF
designed to specifically target flip/flop exons.
To determine the functional outcome of Ledgf knockdown-induced change in Gria2 flip/flop
splicing, we injected lentivirus encoding shLedgf and control shRNA into the cortex of wild type
mice. We found that Ledgf knockdown resulted in a significantly reduced decay time constant τ
of glutamate-evoked AMPAR-gated current (Fig 6j), an effect similar to that caused by the loss
of MeCP2 (Fig 6a and 6b). In addition, Ledgf knockdown led to significantly weaker response
upon repetitive stimulations (Fig 6k and 6l), another phenotype caused by the loss of MeCP2
(Fig 6h and 6i). These data correlate well with theGria2minigene assay in Fig 5 and further sup-
port that both LEDGF andMeCP2 are required for the normal splicing of Gria2 flip/flop exons.
Discussion
MeCP2 has been previously implicated in regulating alternative splicing of RNA in two studies.
In 2005, Young et al reported RNA-dependent interaction between MeCP2 and YB1 in a neu-
roblastoma cell line forced to overexpress MeCP2 and some changes in alternative splicing in
theMecp2308/y brain[23]. In 2013, Maunakea et al reported intragenic DNAmethylation-
dependent MeCP2 binding to alternatively spliced exons in cancer cell lines[48]. Our work
substantially extends these previous studies in several ways, and to our knowledge, this is the
first report of the functional consequence for MeCP2-mediated splicing.
First, the physical interaction between MeCP2 and its interacting partners identified in our
study are independent of any nucleic acid, suggesting that MeCP2 does not need to bind to RNA
in order to regulate splicing. Additionally, these physical interactions have more physiological
relevance, because they were identified in the mouse brain where MeCP2 is expressed from its
endogenous locus. Furthermore, we identified multiple splicing factors as novel MeCP2-inter-
acting partners in the brain. Since these factors are not part of the core splicing machinery but
rather affect splicing as accessory splicing factors[55], the biochemical mechanism underlying
their involvement in splicing regulation is not well known. Their interaction with MeCP2, a
known chromatin protein, provides novel clues for studying how these factors regulate splicing.
In addition, because we used a different RTTmouse model (Mecp2 KOmice in our study vs.
Mecp2308/ymice in Young et al[23]) and a more sensitive method to profile alternative splicing
(RNA-seq vs. microarray), the altered splicing events identified in our study were different from
those previously identified by Young et al[23]. Nonetheless, combining results from three inde-
pendent unbiased approaches (Co-IP mass spectrometry, RNA-seq and ChIP-seq), our study
provides strong evidences for a significant involvement of MeCP2 in regulating RNA splicing.
Second, we discovered significant MeCP2 occupancy around exon/intron boundary and
exons in the mouse brain, and characterized gene exon specific interaction between MeCP2
and two splicing regulators, providing a potential mechanism for MeCP2-dependent splicing
regulation. Recent evidence suggests intragenic DNAmethylation recruits MeCP2 and regu-
lates pre-mRNA splicing through altering DNA polymerase II elongation rate[48]. However,
our data suggests that it is not responsible for the altered flip/flop splicing in the cortex of
Mecp2 KOmice. Instead, our results suggest a new model that co-occupancy of MeCP2 and
LEDGF on the chromatin is required for the normal flip/flop splicing in the Gria2 gene.
Finally, and most importantly, we established a functional link between specific splicing
changes caused by the loss of MeCP2 function to synaptic changes in RTTmice. The fact that a
ESF specifically rescues the flip/flop splicing defect can reverse the corresponding synaptic
changes in RTT brain strongly suggest that the specific change in synaptic property (AMPAR
kinetics) is caused by altered flip/flop splicing. Given the central role of AMPARs in synaptic
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transmission, it is likely the altered AMPAR kinetics will lead to altered synaptic functions other
than the repetitive stimulation paradigm employed in our study. Future study is needed to mech-
anistically link the altered AMPAR kinetics with specific neuronal defects in RTT symptoms, and
to evaluate the effect of reversing flip/flop splicing on RTT disease progression. In addition to the
flip/flop choice in AMPARs, alterative splicing of several other genes (e.g.Nrxn1, Dscam, lin7a)
that play important roles in synaptic functions were changed in the RTTmouse cortex, indicating
that additional synaptic changes may be caused by splicing deficits. Thus, altered RNA splicing
appears to be a novel molecular mechanism underlying synaptic dysfunction in RTT.
Splicing misregulation has been increasingly recognized as a significant contributor to a
number of neurological diseases, such as SMA[56], FTDP-17[27], ALS[57] and myotonic dys-
trophy[58]. The mechanistic study of how the genes mutated in neurological diseases can
directly affect alternative splicing, as well as the functional consequences of splicing alteration
in such diseases, will have important implications in human health. Our study adds to the
growing list of studies on the novel links between specific events of altered splicing and neuro-
logical diseases.
Materials and Methods
Ethics statement
All animal procedures were performed according to protocols approved by the Institutional
Animal Care and Use Committee at the University of Wisconsin-Madison. All mice in this
study were euthanized by CO2 asphyxiation, according to the guidelines of the RARC at the
University of Wisconsin-Madison and the recommendations of the Panel on Euthanasia of the
American Veterinary Association.
Animals
TheMecp2-Flag mice have a Flag sequence inserted intermediately before the stop codon of
theMecp2 locus[34]. TheMecp2 KOmice used in this study are the Jaenisch strain
(Mecp2tm1.1jae)[59]. Mice were housed in a facility with 12-hr light/12-hr dark cycle.
Plasmids
pRK5-HA-MeCP2-WT, Δ1–77, Δ1–162, Δ78–162 and Δ381–492 were a gift from Dr. Zilong
Qiu[25]. DNA encoding Δ163–380, MeCP2R168X, MeCP2R255X, MeCP2R270X and MeCP2R290X
were PCR amplified and inserted into pRK5-HA by replacing the sequence between SalI site
and NotI site of pRK5-HA-MeCP2 using Gibson cloning (NEB). To construct Myc-tagged pro-
tein expression plasmid, cDNA of LEDGF/p52, LEDGF/p75, and DHX9 were amplified from a
mouse cortex cDNA library using a Myc sequence-containing primer and inserted into pRK5
backbone. LEDGF is also known as Psip1. Engineered splicing factor (ESF) were designed to tar-
get the Flip (GCCAAGGA) and the Flop (GCAGCGGG) exons[38]. Gria2 minigene was con-
structed by amplifying Gria2 Exon13 to Exon15 frommouse genomic DNA and inserted into
pEGFP-C1 backbone. The Ledgf shRNA (shLedgf) target sequence (5’-GCA GCT ACT GAA
GTC AAG ATT C-3’) was adapted from a previous study[60] and cloned into pLL3.7 backbone.
TheMecp2 shRNA (shMecp2) construct was used in our previous study[61]. A scrambled
sequence (5’-GGA ATC TCA TTC GAT GCA TAC-3’) was used as negative control (shCtrl).
Co-immunoprecipitation and mass spectrometry
Nuclei were extracted from the whole brain of WT andMecp2-Flagmice as previously
described[62]. Purified nuclei were resuspended in lysis buffer containing 20mM Tris, 150mM
Misregulation of Alternative Splicing in a Mouse Model of Rett Syndrome
PLOSGenetics | DOI:10.1371/journal.pgen.1006129 June 28, 2016 15 / 25
NaCl, 1.5mMMgCl2, 1mM EDTA, 10% Glycerol, 0.2% NP-40 and 1X proteinase inhibitors
cocktail (Roche) and sonicated using a Misonix 3000. After centrifuging at 20,000g for 20min
at 4°C, supernatant was incubated with 50ul of Anti-Flag M2Magnetic Beads (Sigma) over-
night at 4°C. In the following day, beads were washed with lysis buffer for 6 times. Bound pro-
tein was eluted by competition with 100 mg/ml of Flag Peptide (Sigma F3290). Eluted proteins
from 5 IPs per genotype were pooled together and precipitated by adding 8 volume of pre-
chilled acetone. Pellet was resuspended in 100mM Ammonium Bicarbonate solution. After
DTT and IOAA treatment, protein was digested into peptides using Trypsin Gold (Promega)
and Proteinase Max (Promega) overnight at 37°C. Peptides were separated by a nano HPLC
and analyzed by a Thermo LTQ mass spectrometer. MS/MS spectra data was analyzed using
Bioworks software (Thermo). Only proteins identified in Flag IP eluate fromMecp2-Flagmice
but not WT mice were considered to be potential MeCP2-interacting proteins.
Co-immunoprecipitation and western blot
Co-IP was performed as described above except using Dynabeads (Life Technologies). For co-
IP with Benzonase treatment, lysate was treated with 250 Unit of Benzonase per mouse brain
for 1hr at 4°C before incubating with beads. Proteins were eluted by adding 1X LDS sample
buffer (Life Technologies) and heated at 95°C for 10min.
Proteins were resolved in a 10% SDS-PAGE gel and transferred into a nitrocellulose mem-
brane. Membrane was blocked with 5% non-fat milk in PBS for 1 hour followed by incubat-
ing with primary antibody overnight at 4°C. Membrane was washed 3 times with PBST and
incubated with DyLight Fluor Secondary Antibodies (Pierce) for one hour at room tempera-
ture. Membrane was imaged on a LI-COR Odyssey Imager. Western blot quantification was
done using ImageJ. Primary antibodies used in this study were: anti-DHX9 (Abcam ab26271,
1:2000), anti-FLAG (Sigma M2, 1:1000), anti-FUS (Bethyl A300-293A, 1:10000), anti-HA
(Covance MMS-101P, 1:5000), anti-hnRNP F+H (Abcam ab10689, 1:3000), anti-LEDGF
(Bethyl A300-847A, 1:1500), anti-MeCP2 (Abcam ab50005, 1:2000), anti-Myc (Cell signaling
71D10, 1:1000), and anti-TDP-43 (ProteinTech 10782-2-AP, 1:1000).
Transfection and co-immunoprecipitation
HA-MeCP2 construct was co-transfected with Myc-LEDGF or Myc-DHX9 (1:1 ratio) into
HEK293 cells using GenJet transfection reagent (Signagen). 24 hours after transfection, cells
were washed with PBS twice and directly lysed with Pierce IP Lysis Buffer (Thermo Scientific)
for 10min on ice. Lysate was centrifuged at 16,000g for 10min at 4°C and pellet was discarded.
Six hours before lysate preparation, 30ul Dynabeads protein G was incubated with 3ug of anti-
HA (Covance) or anti-Myc (Millipore) at 4°C to form the antibody-proteinG-bead complex.
After washing off excess antibody, beads were incubated with lysate overnight at 4°C. Beads
were washed with lysis buffer 6 times and then eluted by adding 1X LDS sample buffer (Life
Technologies) and heated at 95°C for 10min.
RNA-Seq analysis
Total RNA was extracted from cortices of 6-weeks-old WT andMecp2 KOmice using Qiagen
RNeasy Mini Plus kit. Genomic DNA was removed by a gDNA Eliminator column. 150ng
total RNA was used to prepare sequencing library according to manufacturer’s instructions
(Nugen Encore Complete). Each Library was subject to one lane of 100bp single end sequenc-
ing using Illumina Hi-Seq 2000. Reads were mapped to the mouse genome (mm9) using
Tophat (2.0.8). Reads count for each gene was calculated using htseq-count function in the
HTSeq package. Differential gene expression analysis was done using edgeR in R. Splicing
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analysis was performed using the Mixture of Isoforms pipeline (MISO 0.4.7). Considering the
high similarity of the two replicates for each genotype (Correlation = 0.98 for each), reads from
two replicates were combined for each genotype and processed with MISO. A stringent filter
(total reads for the event 1000, reads supporting inclusion or exclusion isoform 50, total
reads supporting inclusion and exclusion isoform 100, |ΔPSI| 0.20 and Bayes-factor 20)
was used to generate a list of differential splicing events. Read density plot was generated using
sashimi plot built in MISO.
RNA-Seq data from Chen et al[35] and Gabel et al[9] were processed as above for splicing
analysis. A less stringent filter (total reads for the event 20, |ΔPSI| 0.05 and Bayes-
factor 1) was applied to allow for generating more events for further overlap analysis.
Gene Ontology analysis
Gene Ontology (GO) analysis was done using DAVID[63]. Briefly, official gene symbols were
submitted to DAVID. We used our own RNA-seq data and applied a cutoff of RPKM 0.5 to
generate a list of genes expressed in the mouse cortex (13846 genes). This set of genes expressed
in the mouse cortex was used as background for all GO analysis in this manuscript. Terms with
Benjamini adjusted P-value< = 0.05 was considered as significant.
RNA extraction and qRT-PCR
Total RNA was extracted from cortices of 6-8-week-old wild type (WT) andMecp2 KOmale
mice or 15-18-month-old WT andMecp2 KO female mice using Qiagen RNeasy Mini Plus kit
with on-column DNase treatment. RNA extraction from HEK293 or N2A cells was performed
using TRIzol (Life Technology). RNA was reverse transcribed into cDNA using qScript cDNA
SuperMix (Quanta Biosciences). qPCR was performed on an ABI Step-One plus machine
using SYBR Green qPCRMaster Mix (Biotool). Gapdh was used as endogenous control and
2−ΔCt method was used to calculate fold change. See S8 Table for primer sequence.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed as previously reported[29]. Briefly,
cortex tissue was dissected from 6-8-week-old mice, minced and crosslinked in 1% formalde-
hyde (wt/vol) and sonicated using a Misonix 3000. Antibody was first bound to Dynabeads
and then incubated with sheared chromatin overnight at 4°C. After 4 washes with RIPA buffer
and 1 wash with TE buffer, bound chromatin was eluted and reverse crosslinked at 65°C over-
night. Eluted DNA was treated with RNase A (Thermo Scientific) and proteinase K (Promega),
purified by phenol-chloroform extraction and dissolved in water. Antibodies used were: anti-
Flag (Sigma M2), anti-LEDGF (Bethyl A300-847A), anti-H3K36me3 (Abcam ab9050), and
anti-PolII (Abcam ab5408). Primer sequence for ChIP-qPCR is provided in S8 Table.
ChIP-seq data analysis
ChIP-Seq data were generated from two biological replicates (referred to as WT1 and WT2).
Raw data was aligned to the mouse genome version mm9 with Bowtie (0.12.7). After excluding
non-mapping reads, we had 72, 221, 924 reads for WT1 ChIP and 31, 333, 769 for its input and
84, 871, 157 reads for WT2 ChIP and 22, 412, 408 for its input. We firstly evaluated the quality
of these data with respect to ENCODE’s ChIP-seq quality control metrics[64]. The Normalized
Strand Cross Correlation (NSC) for WT1 ChIP andWT2 ChIP is 1.3 and 1.4, respectively.
Another quality control measure is PCR Bottleneck Coefficient (PBC), which gives an estimate
of the complexity of the ChIP-seq library[65]. PBC<0.5 indicates PCR bottlenecks are present
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in sequenced libraries. The PBC ranged within [0.63 0.83] across WT1 ChIP sample and [0.85,
0.94] for the WT1 input sample. Similarly, the PBC ranged within [0.63 0.83] across WT2
ChIP sample and was 0.93 for the WT2 input sample. These numbers suggest our libraries
were of good quality.
We carried out peak calling using MOSAiCS package in R[66] using default parameters
except for fdrRelaxed = 0.1 for WT1 and WT2 and fdrRelaxed = 0.2 for pooled replicates. Bin
and fragment sizes were set to 200 bps for all the runs. We followed a conservative strategy and
obtained peaks for individual replicates at false discovery rate of 0.1 and for pooled sample run
at 0.2. Then, we identified the peaks in the intersection of the three peak lists and filtered them
with mosaics parameters: logMinP> = -log10(0.05) & peakSize> = 150 & aveLog2Ratio> =
log2(1.5). This resulted in a total of 20, 652 peaks with median size of 1731 bps. We performed
location analysis using mm9 Refseq genes and the nomenclature in Blahnik et al[67].
Analysis of the level of CG methylation, CHGmethylation, and CHH
methylation in MeCP2 ChIP-Seq peaks
The previously published independent datasets were used[42]. DNA methylation data in the
frontal cortex of adult mouse (10-wk-old) were downloaded under accession number GSM
1173784. Each context of the cytosine methylation and the two following bases from the same
strand was considered independently: CG, CHG or CHH (where H = A, C or T). To determine
the frequency of each context, the frequency of the cytosine methylation of each context in
MeCP2 ChIP-seq peaks was estimated as the average of ratio /(x) = nm(x)/ntot(x), where nm(x)
is the number of reads supporting a methylated cytosine at position x and ntot(x) is the total
number of reads at that position.
Gria2 minigene splicing assay
ESF construct was co-transfected into 293 cells with Gria2minigene (8:2 ratio) using GenJet
transfection reagent (Signagen). To test the effect ofMecp2 knockdown on Gria2 splicing,
shMecp2,Mecp2 overexpression construct and Gria2 minigene (4.5:4.5:1 ratio) was co-trans-
fected into N2A cells with using GenJet. To test the effect of Ledgf knockdown on Gria2 splic-
ing, shLedgf construct and Gria2minigene (9:1 ratio) was co-transfected into N2A cells using
GenJet. Cells were lysed in TRIzol 48 hours after transfection for qRT-PCR analysis.
Electrophysiology
Male mice at 4–6 weeks postnatal were used. Coronal brain slices (400 μm) were prepared in
ice-cold modified artificial cerebrospinal fluid (aCSF) (in mM: 124 NaCl, 2.5 KCl, 1 CaCl2, 2
MgSO4, 1.25 NaH2PO4, 26 NaHCO3, and 15 glucose) bubbled with 95%O2/5%CO2. Then the
slices were incubated in normal aCSF (in mM: 124 NaCl, 2.5 KCl, 2.5 CaCl2, 1.2 MgSO4, 1.25
NaH2PO4, 25 NaHCO3, and 15 glucose) at room temperature for at least 1 hour and then
transferred to a submerged recording chamber perfused with 95%O2/5%CO2 saturated aCSF
for electrophysiological recordings. Whole-cell recording of mEPSCs and outside-out patch
recording of glutamate-evoked currents was performed from the Layer 2/3 pyramidal neurons
at room temperature. TTX (1 μM), D-APV (20 μM), bicuculline (50 μM) were added into the
perfused aCSF to block voltage gated Na+ channels, NMDA receptors and GABA receptors
respectively. The patch pipette (3–4 MO) solution contained (in mM): 140 Cs-Gluconate, 7.5
CsCl, 10 HEPES, 0.5 EGTA-Cs, 4 Mg-ATP, and 0.3 Li-GTP, pH 7.4. Raw data were amplified
with a Multiclamp 700B amplifier and acquired with pClamp10.2 software (Molecular
Devices). Neuronal currents were recorded under voltage clamp at the holding potential of -70
mV. An ALA fast perfusion system was used to perform application of glutamate (10 mM). In
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some experiments, CTZ (50 μM) was added. The detection of mEPSCs and exponential fitting
were performed using Clampfit 10.2. The decay of glutamate evoked currents was fitted with
double-exponential functions, and the fast- and slow- time constant were obtained. Signals
were filtered at 2 Hz and sampled at 10 kHz by Digidata 1440A (Molecular Devices). mEPSCs
were analyzed using the Template Search tool of the Clampfit10.2. To create the template, sev-
eral well-shaped mEPSCs traces were picked and averaged to the template window. The
mEPSCs events were accepted manually. Amplitude and the weighted time constant of decay
phase of both mEPSCs and glutamate evoked currents were acquired.
To investigate whether enhanced depression of AMPAR responses to burst-type stimula-
tions is expressed at synapses, we recorded excitatory postsynaptic potentials evoked through a
bipolar stimulating electrode (FHC Inc.) placed in the white matter (eEPSCs, five pulses at 10
Hz). AMPAR-mediated eEPSCs were recorded in the presence of D-APV (20 μM) and bicucul-
line (50 μM) at a holding potential of -70 mV. The data was analyzed with Clampfit 10.
Lentivirus preparation and stereotaxic injection
Lentivirus preparation was performed as described[68] except that we use minimum amount
of media (leftover in the tubes) to resuspend the virus. Stereotaxic injection was done as previ-
ously described[61].
AAV infection
Custom AAV encoding ESF was generated by Vigene. DIV7 primary cortical neurons were
infected with AAV at a MOI of 105. AAV was removed 48 hours after infection and cells were
collected 7 days after infection for qRT-PCR analysis.
Statistics
No statistical procedure was used to predetermine sample size. Student’s t-test was used to
compare means between two groups. Multiple t-test comparisons were corrected using Benja-
mini-Hochberg procedure. One-way ANOVA followed by Tukey’s multiple comparison tests
was used to test difference in experiments with multiple groups. Two-way ANOVA with
repeated measure followed by Bonferroni's multiple comparisons test was used for analysis in
the repetitive stimulation experiments. Statistical calculation was performed using Microsoft
Excel and Graphpad Prism.
Supporting Information
S1 Fig. Interaction between MeCP2 and splicing factors is not dependent on DNA or RNA.
Co-immunoprecipitation was performed in nuclear extract pretreated with or without Benzo-
nase, which degrades nucleic acids in the lysate. Proteins were resolved in SDS-PAGE and
probed with indicated antibodies. A previously known MeCP2-interacting protein, HDAC1, is
shown as a control.
(TIF)
S2 Fig. Deletion of amino acids 163–380 in MeCP2 disrupted interaction with LEDGF. (a)
Western blot analysis of Myc-LEDGF/p75 in anti-HA Immunoprecipitate. HA-MeCP2 and
Myc-LEDGF/p75 were co-transfected into HEK293 cells. Anti-HA immunoprecipitate was
resolved in SDS-PAGE and probed with anti-Myc antibody (Top panel). HA-MeCP2 (middle
panel) and Myc-LEDGF/p52 (bottom panel) in input were also analyzed by Western blot.
Schematics below blots show the configuration of each MeCP2 deletion construct. (b) Western
blot analysis of HA-MeCP2 in anit-Myc immunoprecipitate. HA-MeCP2 and Myc-LEDGF/
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p52 were co-transfected into HEK293 cells. Anti-Myc immunoprecipitate was resolved in
SDS-PAGE and probed with anti-HA antibody (Top panel). HA-MeCP2 (middle panel) and
Myc-LEDGF/p52 (bottom panel) in input were also analyzed by Western blot. Arrow indicates
where MeCP2Δ163–380 band would be if there is one. Star indicates the MeCP2Δ381–492 band
overlapping with IgG. Schematics below blots show the configuration of each MeCP2 deletion
construct.
(TIF)
S3 Fig. Differential gene expression analysis of RNA-Seq data. (a-b) Quantification of MeC-
P2-repressed genes (a) and MeCP2-activated genes (b) in WT andMecp2 KO cortex by RT-
qPCR. Three to four previously known targets and three novel targets identified only in our
RNA-Seq data in each group were selected for validation. Mean ± S.E.M is plotted; n = 5–6 per
genotype.  P< 0.01,  P< 0.001; two-tailed t-test with Benjamini-Hochberg correction. (c)
Good correlation between qRT-PCR result and RNA-Seq analysis result of the 13 genes ana-
lyzed in a-b. r, correlation coefficient.
(TIF)
S4 Fig. Functional enrichment analysis of genes with splicing changes, alignment of
MeCP2 ChIP signal on all genes in the genome, and alignment of mCG%, mCH%, and
hmC% on all exons in the genome. (a) Significant terms (Benjamini P-value< 0.05) were
shown with one redundant term omitted. (b) Read counts per millions of mapped reads (ChIP
minus input) across regions spanning from 2,000bp upstream and 2,000bp downstream of all
genes. Coverage for ChIP and input data are calculated for each biological replicate and nor-
malized to be equal length across all the mm9 genes by sampling at equal intervals. Displayed
is the average ChIP minus input profile of two biological replicates. TSS: transcription start
site. TES: transcription end site.(c) Percentage of CG methylation across regions spanning
from 500bp upstream and 500bp downstream of all exons in the genome. (d) Percentage of CH
methylation across regions spanning from 500bp upstream and 500bp downstream of all exons
in the genome. (e) Percentage of hydroxymethylation across regions spanning from 500bp
upstream and 500bp downstream of all exons in the genome.
(TIF)
S5 Fig. Validation of splicing changes by qRT-PCR. For each splicing event, specific primers
for inclusion isoform and exclusion isoform were designed. Inc / Exc ratio was calculated using
2-ΔCt method. Mean ± S.E.M is plotted; n = 5–6 per genotype.  P< 0.05,  P< 0.01, 
P< 0.001; two-tailed t-test with Benjamini-Hochberg correction.
(TIF)
S6 Fig. Raw data tracks of MeCP2 ChIP-seq reads and input reads over the entire Gria2
gene locus.
(TIF)
S7 Fig. Validation of MeCP2 peaks identified by ChIP-Seq. ChIP-qPCR was performed
using primers specific to each peak. Mean ± S.E.M; n = 4;  P< 0.05,  P< 0.01, 
P< 0.001; one-way ANOVA followed with Holm-Sidak's multiple comparisons test.
(TIF)
S8 Fig. Gria2 flip/flop splicing is altered in multiple brain regions ofMecp2 KOmouse and
the hypothalamus ofMecp2 overexpression (OE) mouse. RNA-Seq read density around flip
and flop exon in indicated brain region of WT and KO (or OE) mouse. Percentage of flip iso-
form (φ) is shown to the right of density plot. Δφ (KO or OE—WT) was calculated and the
Bayes factor (BF) is shown below. Difference in Δφ among different studies might reflect
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difference of brain region, the knockout allele (cortex data was generated from the Jaenisch allele
and the others Bird allele), age of mice when tissue was collected (cortex: 6 weeks of age; hypo-
thalamus: 7 weeks of age; visual cortex: 8–9 weeks of age) and other experimental conditions.
(TIF)
S9 Fig. Engineering splice factor (ESF) can modulate Gria2 flip/flop splicing. (a) Schematic
diagram of the Gria2minigene. The ESF binding site on flip or flop exon is shown. (b-c) Quan-
tification of Gria2 flip/flop ratio (b) and total Gria2mRNA level (c) in primary culture neurons
infected with AAV-Ctrl or AAV-ESF-flop-Gly. Mean ± S.E.M of three independent experi-
ments,  P< 0.01; two-tailed t-test.
(TIF)
S1 Table. MeCP2-interacting proteins identified by coIP-MS.
(XLSX)
S2 Table. Gene expression fold change (log2FC[KO/WT]) of 315 MeCP2-repressed genes
defined by a recent meta-analysis.
(XLSX)
S3 Table. Lists of splicing events significantly changed inMecp2 KO cortex.
(XLSX)
S4 Table. Summary of MISO analysis comparisons between our study, Chen et al 2015
PNAS and Gabel et al 2015 Nature.
(XLSX)
S5 Table. Lists of overlapping splicing changes between our study (cortex) and Chen et al,
2015, PNAS (hypothalamus).
(XLSX)
S6 Table. Lists of overlapping splicing changes between our study (cortex) and Gabel et al
2015 Nature [9] (Visual cortex).
(XLSX)
S7 Table. Lists of MeCP2 ChIP-Seq peaks (Highlighted peaks were validated by ChIP-
qPCR.).
(XLSX)
S8 Table. List of all PCR primers used in our study.
(XLSX)
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